FeesSafety
Pluang+

Helus Pharma reports Q2 2027 results, completes Phase 3 enrollment for depression drug, plans anxiety study in 2027

Company Fundamentals
16 Nov 2026, 13:00 WIB
GlobeNewsWire
View Source
Bullish
Helus Pharma reports Q2 2027 results, completes Phase 3 enrollment for depression drug, plans anxiety study in 2027

Helus Pharma announced its Q2 fiscal 2027 financial results and key business updates, including completing enrollment in the Phase 3 APPROACH study for HLP003, a treatment for major depressive disorder (MDD), with topline data expected in Q4 2026. The company also plans to start a Phase 2 study of HLP004 for generalized anxiety disorder (GAD) in Q1 2027. Financially, Helus reported a net loss of $103.1 million for the quarter, driven by advancing clinical trials. These developments position Helus to potentially deliver new treatments for mental health conditions in the near future.

Helus Pharma's recent financial report shows a net loss of $103.1 million for Q2 fiscal 2027 amid advancing clinical trials. For readers following the health sector, here is Pluang's market snapshot as of Nov 16, 2026 17:41 WIB: of 150 priced Health-sector US stocks, 60 rose and 50 fell today. Notable movers include Novo Nordisk A/S (NVO) at USD 42.46 with a 1-day change of +1.99%, Revolution Medicines Inc. (RVMD) at USD 169.02 down -1.90%, and Takeda Pharmaceutical Company (TAK) at USD 21.80 up +1.73%.

More News

eGain launches service to prepare enterprise knowledge for reliable AI use without replacing platforms

eGain launches service to prepare enterprise knowledge for reliable AI use without replacing platforms

eGain Corporation introduced the Trusted Knowledge Service, designed to make existing enterprise knowledge AI-ready and reliable without replacing current platforms like SharePoint and Salesforce. The service includes evaluation, preparation, verific...

Market News
Bullish
54 minutes ago
Heineken repurchases over 10 million shares in €1.5 billion buyback program's second tranche

Heineken repurchases over 10 million shares in €1.5 billion buyback program's second tranche

Heineken N.V. has repurchased a total of 10,017,690 shares under the second €750 million tranche of its €1.5 billion share buyback program as of November 13, 2026. The shares were bought both on the exchange and from Heineken Holding N.V., with an av...

Company Fundamentals
Neutral
54 minutes ago
eGain launches Trusted Knowledge Service to prepare enterprise data for reliable AI use without platform changes

eGain launches Trusted Knowledge Service to prepare enterprise data for reliable AI use without platform changes

eGain Corporation has introduced the Trusted Knowledge Service, designed to prepare and certify enterprise knowledge for AI use without replacing existing platforms like SharePoint and Salesforce. The service includes assessment, correction, certific...

Market News
Bullish
54 minutes ago
Credit Agricole Toulouse 31 reports weekly transactions on cooperative investment certificates.

Credit Agricole Toulouse 31 reports weekly transactions on cooperative investment certificates.

Credit Agricole Toulouse 31 disclosed its weekly transactions on cooperative investment certificates (CCI) for the period from November 9 to November 13, 2026. The report details daily volumes and average acquisition prices, showing active buybacks o...

Market News
Neutral
1 hour ago
Euronet and Getnet integrate VAT refund into payment terminals for smoother Tax Free shopping in Spain.

Euronet and Getnet integrate VAT refund into payment terminals for smoother Tax Free shopping in Spain.

Euronet and Getnet, Santander Group's payment platform, have partnered to integrate VAT refund services directly into payment terminals in Spain. This collaboration allows merchants to process Tax Free transactions seamlessly at the point of sale, si...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App